|
|
HER-2零表达乳腺癌患者新辅助治疗后HER-2状态改变与临床病理特征的关系
|
Abstract:
目的：调查HER-2零表达的乳腺癌患者新辅助治疗后HER-2表达状态改变与临床病理特征的关系。方法：纳入2017年1月至2020年1月在青岛大学附属医院乳腺病诊疗中心初次就诊的乳腺癌患者，对他们进行回顾性分析。根据化疗后HER-2状态分为HER-2状态不变的阴性组和HER-2状态改变的阳性组。分析HER-2状态改变与患者临床病理特征之间的联系。结果：纳入的367例患者新辅助治疗后阴性组共有248例，阳性组共有119例。采用χ2检验对患者的临床病理指标进行统计分析。结果显示与阴性组相比，阳性组病例中纯浸润性乳腺癌的比例更高。同时，组织学分级较低，ER阳性率较高，Ki-67小于等于14%的比例在阳性组中也高于阴性组，差异有统计学意义(P < 0.05)。Logistic多因素分析显示：ER、Ki-67、组织学类型、组织学分级是影响HER-2状态改变的独立影响因素(P < 0.05)。结论：近30%的HER-2零表达乳腺癌患者在新辅助治疗后表示出HER-2状态的变化，HER-2状态转变的患者与未转变的患者表现出不同的临床病理特征。
Objective: To investigate the relationship between the change of HER-2 expression status and clinicopathological characteristics in breast cancer patients with zero expression of HER-2 after neoadjuvant therapy. Methods: Patients with breast cancer who were initially diagnosed in the Breast Disease Diagnosis and Treatment Center of the Affiliated Hospital of Qingdao University from January, 2017 to January, 2020 were included in this retrospective analysis. According to HER-2 status after chemotherapy, the patients were divided into the HER-2 status unchanged negative group and the HER-2 status changed positive group. The relationship between HER-2 status and clinicopathological features was analyzed. Results: Among 367 patients, 248 were in the negative group and 119 were in the positive group after neoadjuvant therapy. The chi-square test was used to analyze the clinicopathological parameters of the patients. The results showed that compared with the negative group, the proportion of pure invasive breast cancer in the positive group was higher than that in the negative group. At the same time, the lower histological grade, the higher the ER positivity rate, and the proportion of Ki-67 less than or equal to 14% was also higher in the positive group than in the negative group, with statistically significant differences (P < 0.05). Logistic multivariate analysis showed that ER, Ki-67, histological type and histological grade were independent factors affecting the change of HER-2 status (P <0.05). Conclusions: Nearly 30% of breast cancer patients with HER-2 (0) show a change in HER-2 status after NAT, and patients with HER-2 status transition show different clinicopathological features from those without transition.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Goldhirsch, A., Winer, E.P., Coates, A.S., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, Official Journal of the European Society for Medical Oncology, 24, 2206-2223. |
| [3] | Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu oncogene. Science, 235, 177-182. https://doi.org/10.1126/science.3798106 |
| [4] | Hudis, C.A. (2007) Trastuzumab—Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine, 357, 39-51. https://doi.org/10.1056/nejmra043186 |
| [5] | Vu, T. and Claret, F.X. (2012) Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. Frontiers in Oncology, 2, Article 62. https://doi.org/10.3389/fonc.2012.00062 |
| [6] | Harbeck, N., Beckmann, M.W., Rody, A., Schneeweiss, A., Müller, V., Fehm, T., et al. (2013) HER2 Dimerization Inhibitor Pertuzumab—Mode of Action and Clinical Data in Breast Cancer. Breast Care, 8, 49-55. https://doi.org/10.1159/000346837 |
| [7] | Loibl, S. and Gianni, L. (2017) HER2-Positive Breast Cancer. The Lancet, 389, 2415-2429. https://doi.org/10.1016/s0140-6736(16)32417-5 |
| [8] | Tarantino, P., Hamilton, E., Tolaney, S.M., Cortes, J., Morganti, S., Ferraro, E., et al. (2020) HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 38, 1951-1962. https://doi.org/10.1200/jco.19.02488 |
| [9] | Zhang, H., Katerji, H., Turner, B.M., Audeh, W. and Hicks, D.G. (2022) HER2-Low Breast Cancers: Incidence, HER2 Staining Patterns, Clinicopathologic Features, MammaPrint and Blueprint Genomic Profiles. Modern Pathology, 35, 1075-1082. https://doi.org/10.1038/s41379-022-01019-5 |
| [10] | Fehrenbacher, L., Cecchini, R.S., Geyer Jr, C.E., Rastogi, P., Costantino, J.P., Atkins, J.N., et al. (2020) NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy with or without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and with IHC 1+ or 2+. Journal of Clinical Oncology, 38, 444-453. https://doi.org/10.1200/jco.19.01455 |
| [11] | Modi, S., Park, H., Murthy, R.K., Iwata, H., Tamura, K., Tsurutani, J., et al. (2020) Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer: Results from a Phase IB Study. Journal of Clinical Oncology, 38, 1887-1896. https://doi.org/10.1200/jco.19.02318 |
| [12] | Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., et al. (2017) Safety, Pharmacokinetics, and Antitumour Activity of Trastuzumab Deruxtecan (DS-8201), a HER2-Targeting Antibody-Drug Conjugate, in Patients with Advanced Breast and Gastric or Gastro-Oesophageal Tumours: A Phase 1 Dose-Escalation Study. The Lancet Oncology, 18, 1512-1522. https://doi.org/10.1016/s1470-2045(17)30604-6 |
| [13] | Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387, 9-20. |
| [14] | Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Lo Mele, M., Fassan, M., et al. (2021) Evolution of HER2-Low Expression from Primary to Recurrent Breast Cancer. NPJ Breast Cancer, 7, Article No. 137. https://doi.org/10.1038/s41523-021-00343-4 |
| [15] | Tarantino, P., Gandini, S., Nicolò, E., Trillo, P., Giugliano, F., Zagami, P., et al. (2022) Evolution of Low HER2 Expression between Early and Advanced-Stage Breast Cancer. European Journal of Cancer, 163, 35-43. https://doi.org/10.1016/j.ejca.2021.12.022 |
| [16] | Kang, S., Lee, S.H., Lee, H.J., Jeong, H., Jeong, J.H., Kim, J.E., et al. (2023) Prognostic Implications of HER2 Changes after Neoadjuvant Chemotherapy in Patients with HER2-Zero and HER2-Low Breast Cancer. European Journal of Cancer, 191, Article ID: 112956. https://doi.org/10.1016/j.ejca.2023.112956 |
| [17] | Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Lo Mele, M., Fassan, M., et al. (2022) HER2-Low-Positive Breast Cancer: Evolution from Primary Tumor to Residual Disease after Neoadjuvant Treatment. NPJ Breast Cancer, 8, Article No. 66. https://doi.org/10.1038/s41523-022-00434-w |
| [18] | Hammond, M.E.H., Hayes, D.F., Dowsett, M., et al. (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology & Laboratory Medicine, 134, e48-e72 |
| [19] | Wolff, A.C., Hammond, M.E.H., Allison, K.H., Harvey, B.E., Mangu, P.B., Bartlett, J.M.S., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122. https://doi.org/10.1200/jco.2018.77.8738 |
| [20] | Shao, Y., Guan, H., Luo, Z., Yu, Y., He, Y., Chen, Q., et al. (2024) Clinicopathological Characteristics and Value of HER2-Low Expression Evolution in Breast Cancer Receiving Neoadjuvant Chemotherapy. The Breast, 73, Article ID: 103666. https://doi.org/10.1016/j.breast.2023.103666 |
